Overview

This guidance has been updated and replaced by NICE technology appraisal guidance 933.

People already having tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their NHS clinician consider it appropriate to stop.